Primary care physicians; nurses; physician assistants; and other clinicians who treat patients with type 2 diabetes
Type 2 diabetes; insulin; GLP-1 receptor agonists; hypoglycemia; treatment intensification
Dr. Dungan currently serves as the Associate director of Clinical Services for the OSU Division of Endocrinology, Diabetes & Metabolism and Director of the Endocrine clinical trials unit. She also serves on the division CME committee and on the planning committee for the Endocrine Society Clinical Endocrine Update. Dr. Dungan has published a variety of formats on clinical therapeutics of diabetes, type 1 and type 2. She has a clinical practice in ambulatory and inpatient settings.
Dr. Seley is a Diabetes Nurse Practitioner and Certified Diabetes Educator in the Division of Endocrinology, Diabetes & Metabolism at NewYork-Presbyterian Hospital/ Weill Cornell Medical Center in New York City. She was recently elected to the 2016-2018 Board of Directors of the American Association of Diabetes Educators (AADE) and served on the 2012-2014 AADE board and numerous committees for AADE and the American Diabetes Association (ADA). Jane is contributing editor and column coordinator of the Diabetes Under Control column in the American Journal of Nursing, co-author of the Endocrine Society Guidelines for the management of hyperglycemia in the non-critical care setting, guest editor of the 2014 inpatient management focused issue of ADA's Diabetes Spectrum and has chapters in three recent ADA books. Jane is an active speaker and author committed to both patient and professional diabetes education and the advancement of diabetes technology as a tool to assist people living with diabetes and the clinicians that care for them.| 1. | Accurately evaluate patients with T2DM to determine when insulin initiation/intensification may be necessary | 2. | Compare emerging insulin options with currently available therapies and discuss therapeutic choices with patients |
| 3. | Identify patients who may require insulin intensification to achieve improved prandial control | 4. | Develop strategies to create effective clinician/patient partnerships to maximize effective T2DM management |
| 1. | Accurately evaluate patients with T2DM to determine when insulin initiation/intensification may be necessary |
| 2. | Compare emerging insulin options with currently available therapies and discuss therapeutic choices with patients |
| 3. | Identify patients who may require insulin intensification to achieve improved prandial control |
| 4. | Develop strategies to create effective clinician/patient partnerships to maximize effective T2DM management |



| Supported Browsers: Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6+ for Mac OSX 10.7 and above |